Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Details)

v2.4.0.8
Segment Reporting (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Dec. 31, 2013
Summary of segment information          
Total assets $ 272,283   $ 272,283   $ 104,713
Net revenues from external customers 14,973 13,005 41,539 34,237  
Depreciation and amortization expense (662) (668) (1,998) (2,007)  
Write-off of in-process research and development 0 0 0 480  
Operating (loss) income 3,532 3,070 9,989 8,518  
Interest expense, net (1,516) (394) (1,946) (1,755)  
Income tax expense from continuing operations (124) (60) (131) (237)  
Gain on sale of Avinza Product Line before income taxes 0 0 0 2,588  
Ligand
         
Summary of segment information          
Total assets 203,296   203,296   38,408
Net revenues from external customers 6,424 4,731 18,907 14,789  
Depreciation and amortization expense (61) (62) (194) (179)  
Write-off of in-process research and development       0  
Operating (loss) income (1,683) (1,142) (2,622) (944)  
Interest expense, net (1,516) (394) (1,946) (1,755)  
Income tax expense from continuing operations (115) (70) (123) (301)  
Gain on sale of Avinza Product Line before income taxes   0   2,588  
CyDex
         
Summary of segment information          
Total assets 68,987   68,987   66,305
Net revenues from external customers 8,549 8,274 22,632 19,448  
Depreciation and amortization expense (601) (606) (1,804) (1,828)  
Write-off of in-process research and development       480  
Operating (loss) income 5,215 4,212 12,611 9,462  
Interest expense, net 0    0 0  
Income tax expense from continuing operations (9) 10 (8) 64  
Gain on sale of Avinza Product Line before income taxes   $ 0   $ 0